Howarth P H, Holgate S T
Thorax. 1984 Sep;39(9):668-72. doi: 10.1136/thx.39.9.668.
Ninety patients participated in a randomised, double blind, placebo controlled comparison of terfenadine with astemizole in the treatment of hay fever. They entered the trial as a cohort before the grass pollen season and recorded daily their symptoms of itching eyes, sneezing, running nose, and blocked nose on visual analogue scales in diary cards. Over the eight weeks of the trial astemizole was significantly better than either terfenadine or placebo in alleviating itching eyes, sneezing, and running nose (p less than 0.0001) but no better than placebo for the treatment of blocked nose. The placebo was significantly better than terfenadine for the treatment of running nose and blocked nose (p less than 0.002). Neither of these H1 antihistamine drugs was associated with sedative adverse effects despite significantly inhibiting histamine induced skin weal responses. These results suggest that astemizole is a satisfactory non-sedative H1 antihistamine for maintenance treatment of hay fever. Terfenadine is ineffective by comparison.
90名患者参与了一项随机、双盲、安慰剂对照试验,比较特非那定和阿司咪唑治疗花粉热的疗效。他们在草花粉季节开始前作为一组进入试验,并在日记卡上用视觉模拟量表每日记录眼睛瘙痒、打喷嚏、流鼻涕和鼻塞的症状。在为期8周的试验中,阿司咪唑在缓解眼睛瘙痒、打喷嚏和流鼻涕方面显著优于特非那定或安慰剂(p<0.0001),但在治疗鼻塞方面并不比安慰剂更好。安慰剂在治疗流鼻涕和鼻塞方面显著优于特非那定(p<0.002)。尽管这两种H1抗组胺药能显著抑制组胺诱导的皮肤风团反应,但均未出现镇静不良反应。这些结果表明,阿司咪唑是一种用于维持治疗花粉热的令人满意的非镇静性H1抗组胺药。相比之下,特非那定无效。